About Repligen Corporation
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts. Address: Building 1, Waltham, MA, United States, 02453
Repligen Corporation News and around…
Latest news about Repligen Corporation (RGEN) common stock and company :
These two stocks are posting strong results despite the broader market sell-off.
The declining pace of COVID-19 vaccination programs is likely to hurt Repligen's (RGEN) revenue growth rate in 2022. However, the strong core business is likely to offer a respite.
Here at CryptocurrenciesChannel. om, we find it interesting to track various ETF and stock prices versus various digital assets over time.
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
LRT Capital Management, an investment management firm, published its first-quarter 2022 investor letter – a copy of which can be downloaded here. A return of -7.37% was recorded by the LRT Economic Moat strategy for the first quarter of 2022, resulting in a 12-month return of +16.72%. In the LRT Economic Moat strategy, as of […]
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Repligen Corp. (RGEN) was identified as having a larger market cap than the smaller end of the S&P 500, for example Invesco Ltd (IVZ), according to The Online Investor..
Repligen (RGEN) reports encouraging first-quarter results with both sales and earnings beating estimates. RGEN also reduced its financial guidance for 2022
Needham lowered MKS Instruments, Inc. (NASDAQ: MKSI) price target from $185 to $175. MKS Instruments shares rose 3.6% to $116.01 in ...
Gainers Vivakor, Inc. (NASDAQ: VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed ...
A stronger-than-expected earnings report calls months of the stock's weakness into question.
Gainers Vivakor, Inc. (NASDAQ: VIVK) gained 154% to $4.3550 after the company announced it has signed a 10-year contract with ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech Seeks ...
Repligen (RGEN) delivered earnings and revenue surprises of 27.78% and 12.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Repligen (NASDAQ:RGEN) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:30 AM. Here's what investors ...
—Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency —Organic revenue growth of 44% for the quarter and base business growth of 37% —Growth driven by combination of base business strength, COVID-related demand, and acquisition revenue WALTHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results f
Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is projected to report earnings for its first ...
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms ...
Repligen (NASDAQ:RGEN) will host a conference call at 08:30 AM ET on April 27, 2022, to discuss Q1 2022 earnings results. How to Attend ...
Mid-cap healthcare companies have built up a combination of competitive advantages. This article looks at several top stocks in the segment.
Favored companies include Uber, General Motors and Twilio.
Management has executed its strategy well, but a potential risk is looming.
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares S&P Mid-Cap 400 Growth ETF (IJK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $94.65 per unit.
Webcast and Conference Call to Be Held Wednesday, April 27, 2022 at 8:30 a.m. EDTWALTHAM, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2022 financial results on Wednesday, April 27, 2022. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- month reporting period ended March 31, 2
InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you follow an elephant's tracks, you find an elephant. If you follow a large money manager, you'll find the winners they've identified. The post Elephant Tracking: How to Spot the Market’s Next Mega Winners BEFORE They Take Off appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. 10 Stocks Are Issuing Sell Signals Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Repligen and Exact Sciences have a proven track record with significant opportunities for continued growth.
Let's talk about the popular Repligen Corporation ( NASDAQ:RGEN ). The company's shares saw a double-digit share price...
WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 22-23, 2022. Tony J. Hunt, President & Chief Executive Officer, will participate in a fireside chat on Tuesday, March 22, at 9:45 a.m. EDT. A live webcast of the presentation will be accessible through Repligen’s Investor
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core S&P Mid-Cap ETF (IJH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $323.04 per unit.
Repligen Corporation (RGEN) is a NASDAQ Common Stock listed in Common Stock, Healthcare, Medical Instruments & Supplies
